^
    1d
    4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2030 | Trial primary completion date: Nov 2020 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    4SCAR-T • GD2, PSMA and CD276 CAR-T
    1d
    Multi-CAR-T Cells Targeting B Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=11, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2030 | Trial primary completion date: Jul 2023 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule) • CD70 (CD70 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    multi-CAR-T cell therapy
    1d
    PSMA-specific CAR-T Cell Therapy (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Oct 2023 --> Oct 2029
    Trial completion date • Trial primary completion date
    2d
    Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer. (PubMed, Clin Cancer Res)
    P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effector-related toxicities were observed in some patients, a novel iCasp9 safety switch was largely effective in mitigating toxicity.
    Journal
    |
    CASP9 (Caspase 9)
    2ms
    2022-BRL-501: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Shanghai Changzheng Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> May 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV
    2ms
    Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Shanghai Changzheng Hospital | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    3ms
    PERSIST: Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials (clinicaltrials.gov)
    P=N/A, N=178, Enrolling by invitation, AvenCell Therapeutics, Inc.
    New trial
    4ms
    Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). (PubMed, Clin Cancer Res)
    Robust expansion of P-PSMA-101 CAR T cells resulted in toxicity but also durable responses in patients with mCRPC. Future trials of CAR T may be informed by the results with this nonviral engineering, TSCM cell-enriched approach.
    P1 data • Journal • IO biomarker
    |
    CASP9 (Caspase 9)
    6ms
    TmPSMA-02 in mCRPC (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Pennsylvania | Active, not recruiting --> Recruiting
    Enrollment open
    |
    TmPSMA-02
    9ms
    TmPSMA-02 in mCRPC (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=18 --> 8
    Enrollment closed • Enrollment change
    |
    TmPSMA-02
    12ms
    Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • engineered autologous T cells
    1year
    Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging. (PubMed, Proc Natl Acad Sci U S A)
    Herein, we develop an approach for in situ T cell generation, tracking, and functional assessment using anti-CD5-conjugated lipid nanoparticles for codelivering CD19 CAR mRNA (mCAR19) and a prostate-specific membrane antigen mRNA (mPSMA) tag. With interleukin-7 (IL-7) preconditioning and repeated administration, this approach achieves tumor-free survival in 75% of B cell lymphoma-bearing mice (similar efficacy to ex vivo approaches), and through PET imaging of 68Ga-PSMA-617, the generation and tumor infiltration of in situ-engineered PSMA-tagged CD19 CAR-T cells is validated.
    Journal
    |
    IL7 (Interleukin 7)